Teva Pharmaceutical Industries Limited (NYSE:TEVA) Holdings Lifted by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 34,543,812 shares of the company’s stock after acquiring an additional 2,204,623 shares during the period. Teva Pharmaceutical Industries makes up about 5.5% of Clal Insurance Enterprises Holdings Ltd’s holdings, making the stock its 4th largest holding. Clal Insurance Enterprises Holdings Ltd’s holdings in Teva Pharmaceutical Industries were worth $621,337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Eagle Asset Management Inc. grew its holdings in Teva Pharmaceutical Industries by 41.5% during the 3rd quarter. Eagle Asset Management Inc. now owns 38,857 shares of the company’s stock valued at $665,000 after buying an additional 11,401 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Teva Pharmaceutical Industries by 24.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company’s stock valued at $16,203,000 after purchasing an additional 177,836 shares during the last quarter. Smithfield Trust Co lifted its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $439,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $14,840,000. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays increased their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Up 0.2 %

TEVA opened at $17.12 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $9.35 and a 52 week high of $19.31. The stock’s fifty day moving average is $17.70 and its two-hundred day moving average is $17.30. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.